Courts May Not Rule on Invalidity of Unasserted Claims
Client Alert | 1 min read | 09.09.08
In 800 Adept, Inc. v. Murex Securities, Ltd., et al. (Nos. 2007-1272, -1356; August 29, 2008), the Federal Circuit affirms a trial court's judgment of invalidity of certain asserted patent claims, reverses the trial court's judgment of invalidity with respect to unasserted patent claims and of tortious interference, and vacates the trial court's judgment on infringement and invalidity of certain claims.
In reversing the trial court's judgment of invalidity on the unasserted claims, the Federal Circuit determines that the unasserted claims were not placed at issue in the litigation and, therefore, the trial court erred in ruling on the validity of the claims. The Court noted that the assertions of validity must have been "actually litigated by the parties" for there to be a finding of invalidity.
In construing claims as the basis for vacating the finding of infringement, the Federal Circuit uses the prosecution history to support the construction of claims discerned from the claim language and written description, even though the particular claim limitation being construed was not part of the prosecution history at the time certain statements were made. The court finds that since the applicant was "quite clear throughout prosecution that his invention" operated in a certain way, it can be used to support the claim construction discerned from other intrinsic evidence.
Insights
Client Alert | 4 min read | 08.29.25
Gender-Affirming Care Targeted for Potential False Claims Act Enforcement
On August 19, 2025, the Office of Personnel Management (OPM) informed insurers participating in the Federal Employees Health Benefits or Postal Service Health Benefits programs that gender-affirming care would no longer be covered for federal workers starting in 2026. This coverage decision is the Trump Administration’s latest action stemming from Executive Order 14187 which aims to prevent certain treatments, such as gender-affirming hormone therapy, surgeries, and puberty blockers for those under the age of 19. As previously discussed, the Administration has also signaled its intent to use various law enforcement tools against gender-affirming care, including Section 5 of the Federal Trade Commission Act to police false or unsupported claims by medical professionals about gender-affirming treatments.
Client Alert | 4 min read | 08.28.25
9th Circuit Marches Forward to the Future Finding Digital Assets Are Protected Under Trademark Law
Client Alert | 2 min read | 08.27.25
CPSC Maintains Momentum on eFiling Requirements for Consumer Products
Client Alert | 10 min read | 08.27.25
The New EU “Pharma Package”: Advertising – A Comparison of Commission/Parliament/Council Positions